ClinicalTrials.gg
Not yet recruitingNCT07857083Updated Oct 5, 2026

SniffTrain: Effectiveness of Sniff Training in the Treatment of Post-Viral Anosmia

An interventional study of Sniff Training Kits in Post-viral Anosmia, Anosmia and Hyposmia, sponsored by University of Virginia. Not yet recruiting at 3 sites in United States. Open to participants aged 10 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by University of Virginia · Not applicable, Interventional, and Treatment

How we know

Updated Oct 5, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
204
Allocation
Randomized
Ages
10 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 59 studies in Anosmia with a site in United States — 17 open to participants now, 20 under way, 1 of them phase 3. Anosmia · United States.

Planned enrollment
4th of 43
204 · median 51
Started
2027
the only one that year
No phase
19 of 59
7 open now
Primary completion
2031-07
later than 17 of 19 live
Registered
58th of 59
by date

Among the 59 studies in Anosmia with a site in United States, this one is the 4th largest by planned enrollment of the 43 interventional ones that give a count, is the only one that started in 2027, is one of 19 with no phase, reaches primary completion later than 17 of the 19 other live ones, and was the 58th registered.

Anosmia

180 studies on the registry are indexed under Anosmia; 45 are open to participants now.

Browse Anosmia studies →

Open to participants now

17 of the 59 studies in Anosmia with a site in United States are open now. Recruiting first, the newest first:

11 more — sign in →

All 17 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 31 Anosmia studies recruiting now, 14 (45%) set no upper age limit and 9 (29%) stop at 75 or younger; 3 take children under 18; 16 take healthy volunteers.

This study: 10 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies in Anosmia with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to learn whether a structured smell training program (called "sniff training") can help improve sense of smell and quality of life in people who have experienced a reduced or lost sense of smell following a viral illness (also called post-viral anosmia).

03

Conditions studied

  • Post-viral Anosmia
  • Anosmia
  • Hyposmia

Browse trials for

Keywords

  • smell
  • olfaction
  • odor
  • sniffing
04

Who can participate

Ages eligible
10 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 10 - 60 years old
  • For adults, competent and willing to give
  • For minors, competent and willing to give assent, with informed consent from the parent-guardian
  • Willing to undergo study procedures
  • Able to follow written and verbal instructions in English
  • Be able to report test/questionnaire answers via a computer, tablet, or smartphone interface
  • Have a diagnosis of anosmia or hyposmia resulting from a viral infection of the upper respiratory system, with the time since the initial loss of olfactory function > 3 months and \< 2 years prior

Exclusion criteria

Exclusion Criteria:

  • Aged less than 10 years old, and greater than 60 years old
  • Prisoners
  • Cognitively impaired individuals

    • Individuals who are deemed to not have the capacity to consent by the study team through observation and direct interaction
    • Individuals 50-60 years old who score \<31 on the TICS survey (to rule out potential dementia)
  • Non-English speaking subjects
  • Pregnant or breastfeeding
  • Diseases of the central nervous system (including Alzheimer's disease, multiple sclerosis, Parkinson's disease, Huntington's disease, brain tumors), nasal obstruction (tumors/polyps)
  • History of nasal or sinus surgery
  • History of a severe head injury/concussion
  • History of chronic sinus infections, allergic rhinitis, and active sinonasal disease
  • History of radiation therapy to the head or neck (ever)
  • Recent chemotherapy (within the last year)
  • History of lung/pulmonary disease
  • Diagnosis of an olfactory disorder with an etiology other than a viral infection of the upper respiratory system
  • Use of the following medications (used within 3 months of enrollment):

    • Oral
    • Topical corticosteroids
    • Biologic agents used in the treatment of nasal/sinus inflammation (dupilumab, omalizumab, mepolizumab, tezepelumab)
    • Theophylline nasal spray
    • Nasal vitamin A
    • Nasal sodium citrate
  • A time since loss of olfactory function \< 3 months and > 2 years.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
204 participants (estimated)

Study arms

  • Active comparator
    Arm 1: Sniffing named odors

    Participants randomly assigned to Arm 1 will receive sniff training kits containing four inhaler cartridges, with each cartridge containing a different odor (such as lemon, leather, rose, banana, etc). Odor names will be on the cartridges. Participants are instructed to sniff each inhaler cartridge in the morning and evening for 12 weeks. After this initial 12 weeks, participants will receive a new kit which may contain four different odors. These new inhaler cartridges will be sniffed for an additional 12 weeks. At several points in the study, participants will take smell tests or answer questionnaires to assess their ability to smell, their quality of life, and their psychological and neurological health.

    Other: Sniff Training Kits

  • Active comparator
    Arm 2: Sniffing unnamed odors

    Arm 2 will be identical to Arm 1 with the exception that the inhaler cartridges provided to participants randomly assigned to Arm 2 will not have labels identifying the aroma contained in each cartridge.

    Other: Sniff Training Kits

  • Other
    Arm 3: Control Arm

    Arm 3 will be identical to Arm 2 with the exception that the inhaler cartridges will not contain the same amount of odor as in the inhaler cartridges used in Arm 2.

    Other: Sniff Training Kits

Interventions

  • OtherSniff Training Kits

    This study will test the ability of a structured smell training protocol (called "sniff training") to improved smell function. Participants will be asked to sniff inhaler cartridges containing different USDA GRAS (generally recognized as safe) odors (such as lemon, leather, strawberry, banana, etc). The amount of odor may differ, and odors may or may not be identified on the inhalers. The inhaler cartridge are provided at no charge to study participants in kits that contain four inhalers each.

06

What researchers measure

Primary outcomes

  1. Improvement in Odor Perception

    The investigators will use a highly-validated psychophysical smell test (the Sniffin' Sticks Extended Test) to assess changes in olfactory perception and their duration. This test is the primary outcome measure. The resulting TDI score reflects performance on three related test components that measure odor detection Threshold, odor Discrimination, and odor Identification. The scale is 0-48, with higher scores indicating greater function. Investigators will also administer another highly-validated psychophysical smell test, the University of Pennsylvania Smell Identification Test (UPSIT). The score on this 40 point test will not be used to determine the primary outcome but will allow direct comparisons to some other studies that used this measure (higher scores indicated greater function).

    Time frame: From enrollment to the end-of-study visit at 52 weeks

Secondary outcomes

  1. Improvement in social and emotional loneliness

    Patients with smell loss often experience negative changes in mental health, including increased loneliness. The investigators will use the well-validated De Jong Gierveld short scale questionnaire, composed of six questions, to assess changes in the levels of emotional and social loneliness for each participant. Higher scores on the six-point scale indicates greater loneliness.

    Time frame: From enrollment to the end-of-study visit at 52 weeks

  2. Improvement in quality of life

    Patients with smell loss often experience negative changes in their quality of life. To assess changes in health-related quality of life, the investigators will administer the SF-12v2 Health Survey questionnaire (or alternatively the Child Health Questionnaire for participants younger than 18 years old). The SF12v2 provides summary, norm-based scores for mental and physical components, with scores of 50 corresponding to the US population average. Higher scores indicate better health-related quality of life.

    Time frame: From enrollment to the end-of-study visit at 52 weeks

  3. Changes in olfactory-associated quality of life

    Patients with smell loss often experience negative changes in their quality of life. To assess changes in quality of life aspects that have been previously shown to be correlated with olfactory function, the investigators will administer the olfactory-salient Questionnaire of Olfactory Disorders-Negative Statements (QOD-NS). Higher scores on this 51 point scale indicate a greater negative impact of olfactory dysfunction on quality of life.

    Time frame: From enrollment to the end-of-study visit at 52 weeks

  4. Changes in cognitive function

    Several studies have suggested that smell training can improve cognitive function. The investigators will administer the Montreal Cognitive Assessment (MoCA) to measure changes in multiple domains of cognitive function in study participants. The MoCA will only be administered to participants ages 14 years old and up. Higher scores on this 30 point scale indicate better cognitive performance.

    Time frame: From enrollment to the end-of-study visit at 52 weeks.

07

Study locations

3 sites
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Jul 2031, 54 months later.

Of 50 non-industry interventional studies with no phase under Anosmia, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 37. This study's planned 54 months is above that.

Counting every sponsor, half of 50 studies reached it within 28 months; a quarter within 14 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 25, 2026
First posted
Oct 5, 2026
StartEst.
Jan 5, 2027
Primary completionEst.
Jul 31, 2031
CompletionEst.
Jul 31, 2031
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07857083
Responsible party
Steven Munger (Professor, Otolaryngology-Head & Neck Surgery, University of Virginia) — Principal investigator
First posted
Oct 5, 2026
Start date
Jan 5, 2027 (estimated)
Primary completion
Jul 31, 2031 (estimated)
Completion
Jul 31, 2031 (estimated)
Last update
Oct 5, 2026

Study contacts

Nino McHedlishvili
Contact
nm6s@virginia.edu
434-243-3643
Steven Munger
principal investigator · University of Virginia

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion